Apotex’ Apobiologix biosimilars unit says it “looks forward to further expansion of the portfolio to ensure we continue to support patient needs,” after launching the Bambevi (bevacizumab) biosimilar across Canada, the company’s “first oncology therapeutic treatment.”
In late September Apotex announced Health Canada approval for the biosimilar to Avastin, a product of the company’s strategic partnership...






